Estudo randomizado | Sobrevida com cemiplimabe no câncer de colo de útero recorrente.
11 Fev, 2022 | 14:16hSurvival with Cemiplimab in Recurrent Cervical Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Cemiplimab Prolongs Survival in Recurrent Cervical Cancer – HealthDay